Afatinib (A) Vs Erlotinib (E) As Second-Line Treatment of Patients (pts) with Advanced Squamous Cell Carcinoma (SCC) of the Lung Following First-Line Platinum-Based Chemotherapy: Patient-reported Outcome (PRO) Data from the LUX-Lung 8 Phase III Global Trial.